ANALGESIC USE AND ASSOCIATED ADVERSE EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i6.1738Keywords:
Adverse events, Analgesic, Chronic kidney diseaseAbstract
Background: Chronic kidney disease and pain substantially impact the quality of life and hospital costs worldwide. Treating these conditions can be challenging due to characteristic pharmacokinetic and pharmacodynamic challenges.
Aim: This study aims to identify the correlation between analgesic consumption and adverse outcomes in individuals with chronic kidney disease.
Methods: The study complied with PRISMA 2020 guidelines and applied a timeframe of 2013-2023 to ensure similarity through comparison with existing literature. Specialists used online reference databases such as Pubmed and SagePub to identify review articles, preexisting publications, and incomplete works.
Result: 219 and 112 articles have been extracted from PubMed and SagePub, respectively. In 2013, we collected 12 papers accomplishing specific research criteria, consisting of 8 from PubMed and 4 from SagePub.
Conclusion: Patients with CKD require a strategy to minimize adverse consequences and maximize beneficial effects.
References
1. Queremel Milani DA, Davis DD. Pain Management Medications. In Treasure Island (FL); 2022.
2. IASP. IASP Terminology. International Association for the Study of Pain. 2017.
3. Lambourg E, Colvin L, Guthrie G, Murugan K, Lim M, Walker H, et al. The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis. Kidney Int. 2021;100(3):636–49.
4. Koster-Brouwer ME, Rijsdijk M, van Os WKM, Soliman IW, Slooter AJC, de Lange DW, et al. Occurrence and Risk Factors of Chronic Pain After Critical Illness. Crit Care Med. 2020 May;48(5):680–7.
5. Chi C-C, Wang J, Chen Y-F, Wang S-H, Chen F-L, Tung T-H. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci. 2015;78(3):232–8.
6. Preuss C V, Kalava A, King KC. Prescription of Controlled Substances: Benefits and Risks. In Treasure Island (FL); 2022.
7. Neuman MD, Bateman BT, Wunsch H. Inappropriate opioid prescription after surgery. Lancet. 2019;393(10180):1547–57.
8. Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med. 2010;123(4):367–73.
9. Kimmel PL, Fwu C-W, Abbott KC, Eggers AW, Kline PP, Eggers PW. Opioid prescription, morbidity, and mortality in United States dialysis patients. J Am Soc Nephrol. 2017;28(12):3658–70.
10. Novick TK, Surapaneni A, Shin J-I, Ballew SH, Alexander GC, Inker LA, et al. Prevalence of opioid, gabapentinoid, and NSAID use in patients with CKD. Clin J Am Soc Nephrol. 2018;13(12):1886–8.
11. Lee S-Y, Wang J, Chao C-T, Chien K-L, Huang J-W. Frailty modifies the association between opioid use and mortality in chronic kidney disease patients with diabetes: a population-based cohort study. Aging (Albany NY). 2020;12(21):21730.
12. Zhan M, Doerfler RM, Xie D, Chen J, Chen H-Y, Diamantidis CJ, et al. Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J kidney Dis Off J Natl Kidney Found. 2020 Aug;76(2):184–93.
13. KDIGO CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. New York; 2013.
14. Setiati S, Alwi I, Sudoyo AW, Sumadibrata M, Setiyohadi B, Syam AF. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: Interna Publishing; 2014.
15. Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
16. Han Y, Balkrishnan R, Hirth RA, Hutton DW, He K, Steffick DE, et al. Assessment of Prescription Analgesic Use in Older Adults With and Without Chronic Kidney Disease and Outcomes. JAMA Netw open. 2020 Sep;3(9):e2016839.
17. Pham P-CT, Toscano E, Pham P-MT, Pham P-AT, Pham S V, Pham P-TT. Pain management in patients with chronic kidney disease. NDT Plus. 2009 Apr;2(2):111–8.
18. Nagar VR, Birthi P, Salles S, Sloan PA. Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review. Pain Med. 2017 Aug;18(8):1416–49.
19. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247–55.
20. Davis A; Robson J. The dangers of NSAIDs: look both ways. Br J Gen Pract. 2016;66(645):172–3.
21. Guy GPJ, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017 Jul;66(26):697–704.
22. Zhang X, Donnan PT, Bell S. Guthrie, B28764659: Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. vol. 18. BMC Nephrol. 2017;256.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
